iRhythm Technologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

SAN FRANCISCO, March 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced results from two large real-world retrospective analyses presented at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago, IL. Drawing on data from more than 1.1 million patients who used iRhythm's Zio® long-term continuous monitoring (LTCM) ECG devices, these studies demonstrate that short-term (24–48-hour) monitoring, such as with Holter devices, fails to detect a significant proportion of actionable arrhythmias—even in patients reporting "daily symptoms"—and that Symptom–Rhythm Correlation (SRC) is notably low for most arrhythmias, underscoring that selecti

SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue of $164.3 million, a 24.0% increase compared to fourth quarter 2023Gross margin of 70.0%, a 410-basis point increase compared to fourth quarter 2023Net loss of $1.3 million, a $37.4 million improvement compared to fourth quarter 2023Adjusted EBITDA of $19.3 million, a $16.9 million improvement compared to fourth quarter 2023Cash, cash equ

SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2024 after the close of trading on Thursday, February 20, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRh

Wells Fargo resumed coverage of iRhythm with a rating of Equal Weight and set a new price target of $86.00

Goldman initiated coverage of iRhythm with a rating of Neutral and set a new price target of $78.00

Wolfe Research upgraded iRhythm from Peer Perform to Outperform and set a new price target of $115.00

4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)

4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

10-K - iRhythm Technologies, Inc. (0001388658) (Filer)

8-K - iRhythm Technologies, Inc. (0001388658) (Filer)

8-K - iRhythm Technologies, Inc. (0001388658) (Filer)

iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer

SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering

SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue of $164.3 million, a 24.0% increase compared to fourth quarter 2023Gross margin of 70.0%, a 410-basis point increase compared to fourth quarter 2023Net loss of $1.3 million, a $37.4 million improvement compared to fourth quarter 2023Adjusted EBITDA of $19.3 million, a $16.9 million improvement compared to fourth quarter 2023Cash, cash equ

SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2024 after the close of trading on Thursday, February 20, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRh

SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) --  iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2024. Third Quarter 2024 Financial Highlights Revenue of $147.5 million, an 18% increase compared to third quarter 2023Gross margin of 68.8%, a 260-basis point increase compared to third quarter 2023Unrestricted cash, cash equivalents and marketable securities of $522.0 million as of September 30, 2024 Recent Operational Highlights Strong quarterly registration volume driven by record demand from existing

SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)